Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives

Bibliographic Details
Main Authors:	Alessandro Ottaiano, Massimiliano Berretta, Claudia Von Arx, Monica Capozzi, Michele Caraglia
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-03-01
Series:	Frontiers in Oncology
Subjects:	colorectal cancer KRAS BRAF prognosis therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.852445/full

Similar Items

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
by: Aleksandra Bożyk, et al.
Published: (2021-03-01)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
by: Lauren C. Bylsma, et al.
Published: (2020-02-01)

The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali
by: Ayu Dewi Ni Nyoman, et al.
Published: (2022-03-01)

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
by: Concetta Cafiero, et al.
Published: (2020-06-01)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
by: İvo Gökmen, et al.
Published: (2023-09-01)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
by: Alessandro Ottaiano, et al.
Published: (2021-03-01)

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis
by: Nianyi Li, et al.
Published: (2023-07-01)

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
by: Edita Baltruškevičienė, et al.
Published: (2016-04-01)

ANALYSIS OF MUTATIONS IN KRAS AND BRAF GENES IN COLORECTAL CANCER IN RUSSIAN PATIENTS
by: E. E. Pisareva, et al.
Published: (2016-07-01)

Clinicopathological Characteristics of Colorectal Cancer Patients with Different Mismatch Repair Statuses and Their Correlation with KRAS/NRAS/BRAF Gene Mutations
by: Jinchuan YU, et al.
Published: (2024-11-01)

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician
by: Afrăsânie Vlad-Adrian, et al.
Published: (2019-09-01)

Frequency of KRAS and BRAF mutations in colorectal carcinoma and their association with clinical-pathological characteristics in a tertiary hospital in Kenya
by: Samuel Gakinya, et al.
Published: (2024-09-01)

<i>KRAS</i> and <i>BRAF</i> Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
by: Nuria Garcia-Carbonero, et al.
Published: (2020-01-01)

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
by: Zeng J, et al.
Published: (2023-09-01)

Somatic mutations in colorectal cancer: regional experience
by: Nikolai A. Ognerubov, et al.
Published: (2022-07-01)

INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO
by: V. P. Shubin, et al.
Published: (2020-10-01)

BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
by: Laure Moisset, et al.
Published: (2019-06-01)

Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa
by: Meryem Jafari, et al.
Published: (2022-11-01)

BRAF mutation in colorectal cancer: An update
by: Colombo Alfredo, et al.
Published: (2023-01-01)

Analysis of KRAS, NRAS, and BRAF Mutations, Microsatellite Instability, and Relevant Prognosis Effects in Patients With Early Colorectal Cancer: A Cohort Study in East Asia
by: Yang Li, et al.
Published: (2022-06-01)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
by: Sergiu Pasca, et al.
Published: (2019-10-01)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012-05-01)

Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients
by: Wen-Long Guan, et al.
Published: (2020-11-01)

RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
by: Anna Koumarianou, et al.
Published: (2023-04-01)

Prognostic value of the combination of microsatellite instability and BRAF mutation in colorectal cancer
by: Yang Y, et al.
Published: (2018-09-01)

The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer
by: Omshree Shetty, et al.
Published: (2022-07-01)

Using tumor habitat-derived radiomic analysis during pretreatment 18F-FDG PET for predicting KRAS/NRAS/BRAF mutations in colorectal cancer
by: Hongyue Zhao, et al.
Published: (2024-02-01)

Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers
by: Zhao Liu, et al.
Published: (2025-02-01)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Didik Setyo Heriyanto, et al.
Published: (2022-12-01)

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
by: XuSha Zhou, et al.
Published: (2021-09-01)

Clinical and genetic drivers of oligo-metastatic disease in colon cancer
by: Alessandro Ottaiano, et al.
Published: (2025-02-01)

Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review
by: Michal Eid, et al.
Published: (2022-12-01)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
by: Frifeldt Sanne K, et al.
Published: (2011-03-01)

To Correlate the Expression of KRAS and BRAF V600e with Histological Grades and Variants in Tissue Samples of Colorectal Carcinoma
by: Hina Wasti, et al.
Published: (2023-04-01)

The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
by: Yungchang Chen, et al.
Published: (2023-01-01)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
by: Erik J. vanHelden, et al.
Published: (2019-11-01)

Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?
by: Markus K. Diener, et al.
Published: (2021-07-01)

Prevalence of <it>KRAS</it>, <it>BRAF</it>, and <it>PIK3CA</it> somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
by: Palomba Grazia, et al.
Published: (2012-08-01)

Mutational profile of KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes in colorectal cancer patients in a tertiary care hospital, Dhaka
by: Sharmin Chowdhury, et al.
Published: (2022-10-01)

PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01)